In the Korle-Bu project, Gazelle will be studied in the vaccination clinical to screen children, in the maternity ward for newborns, and in the sickle cell clinic to monitor patients on treatment. This study was funded by CTIP (Catalyzing Pediatric Innovation Grant) and sponsored by the U.S. FDA.
In Ghana, 2% of all babies are born with sickle cell disease (15,000 per year) and 25% of the population has sickle cell trait, yet very few can receive early screening to start treating before the sickle cell disease symptoms occur. Most children in sub-Saharan Africa with sickle cell disease die by their fifth birthday.
Novartis announced in 2019 that they are bringing in low-cost sickle cell treatment in collaboration with the Government of Ghana. Hemex Health is a member of the Novartis Biome and is collaborating with Novartis on sickle initiatives.
Hemex Health products are manufactured in India and are pending India regulatory approval to launch there also.